Adagene Inc. (Nasdaq: ADAG), a biotechnology company focused on antibody-based therapies, will present updated clinical trial data for ADG126 at the ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco on January 25, 2025. The data comes from a Phase 1b/2 trial evaluating ADG126, in combination with Merck’s KEYTRUDA® (pembrolizumab), in patients with microsatellite stable colorectal cancer (MSS CRC).
This open-label, multi-center study previously showed efficacy at a 10 mg/kg dose of ADG126 given every three weeks (Q3W). The new data will cover initial results from a higher dose regimen: a 20 mg/kg loading dose followed by 10 mg/kg Q3W, in combination with pembrolizumab.
ASCO-GI Poster Presentation Details
Title: Updated Phase 1b/2 trial data on muzastotug (ADG126, an anti-CTLA-4 SAFEbody) with pembrolizumab in advanced/metastatic MSS CRC
Date: Saturday, January 25
Time: 7:00 a.m. – 7:55 a.m. Pacific Time
Onsite Location: Moscone West, San Francisco
Abstract Number: 193
Poster Board: H5
The poster will be accessible on Adagene’s website after the presentation.
Virtual KOL Event on Anti-CTLA-4 SAFEbody® ADG126 in Advanced/Metastatic MSS CRC on January 25, 2025
A virtual key opinion leader (KOL) event will be held on January 25, 2025, at 1:00 PM ET. Aurélien Marabelle, MD, PhD (Université Paris-Saclay), Daneng Li, MD (City of Hope), and Marwan Fakih, MD (City of Hope) will join Adagene management to discuss the treatment landscape for advanced/metastatic MSS colorectal cancer and the rationale for CTLA-4 targeting in this patient population. Registration details are available [link omitted].
About Adagene
Adagene Inc. (Nasdaq: ADAG) is a clinical-stage biotechnology company developing novel antibody-based cancer immunotherapies. Adagene uses computational biology and AI to design antibodies addressing unmet medical needs. The company collaborates with global partners leveraging its SAFEbody® technology.
Adagene’s Dynamic Precision Library (DPL) platform—including NEObody™, SAFEbody, and POWERbody™ technologies—underpins its pipeline. SAFEbody technology aims to improve the safety and tolerability of antibody therapies using precision masking to target tumors while minimizing off-target effects.
ADG126 (muzastotug), Adagene’s lead clinical program, is a masked anti-CTLA-4 SAFEbody targeting a specific CTLA-4 epitope on regulatory T cells (Tregs) within the tumor microenvironment. ADG126 is in Phase 1b/2 clinical trials in combination with anti-PD-1 therapy, focusing on metastatic MSS CRC. The SAFEbody platform has potential applications in various antibody-based therapies.
For more information, please visit: [link omitted].
Follow Adagene on [links omitted].
SAFEbody® is a registered trademark in several countries.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC.
Safe Harbor Statement
This release includes forward-looking statements regarding ADG126 clinical results, potential patient benefits, and Adagene’s preclinical and clinical development, regulatory milestones, and commercialization. Actual results may differ due to various factors, including the ability to demonstrate safety and efficacy, regulatory approvals, commercial success, intellectual property protection, reliance on third parties, limited operating history, securing funding, entering into collaborations, and the impact of COVID-19. See Adagene’s SEC filings for further details.
Investor Contact:
Bruce Mackle
LifeSci Advisors
“`